Eosinophilic asthma
Drug research and approvals for eosinophilic asthma: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 22, 2026, 15 studies of eosinophilic asthma are recruiting on ClinicalTrials.gov, Health Canada has authorized 12 drug trials for it since 2013, and the EU has 3 authorised medicines for it.
- Recruiting worldwide: 15
- Trials authorized in Canada: 12
- FDA orphan approvals: 0
- EU medicines: 3
- A Study of Depemokimab in Participants of 6 to 11 Years of AgeNCT07671001 · Phase 3 · GlaxoSmithKline · starts Jun 25, 2026
- Roll-over Study for Participants Who Have Completed a Previous Clinical Study With Benralizumab (Fasenra) and Benefit…NCT07444567 · Phase 3 · AstraZeneca · starts Jul 24, 2026
- A Study of KT-621 Administered Orally to Adult Participants With Moderate to Severe Eosinophilic AsthmaNCT07323654 · Phase 2 · Kymera Therapeutics, Inc. · starts Jan 28, 2026
- A Real-life Observational Study in Severe Eosinophilic Asthma Adult Participant Treated With Benralizumab in ItalyNCT07214753 · Not reported · AstraZeneca · starts Dec 20, 2025
- Depemokimab Asthma Imaging and Bronchoscopy Sub-StudyNCT06979323 · Phase 3 · GlaxoSmithKline · starts Jul 19, 2024
- Therapeutic Relevance of Abnormal Airway Morphology in AsthmaNCT06970080 · Phase 4 · McMaster University · starts Jun 2, 2025
- A Multicentre, Single Arm, Non-interventional, Real-world Study to Assess Demographic Characteristics and Patient…NCT06862206 · Not reported · AstraZeneca · starts Jul 11, 2025
- A Study to Evaluate the Long-term Safety, Pharmacodynamics and Efficacy of SHR-1703 in Eosinophilic Asthma PatientsNCT06441812 · Phase 2 · Guangdong Hengrui Pharmaceutical Co., Ltd · starts Jul 19, 2024
- A Non-interventional, Prospective Study With BenralizumabNCT06422078 · Not reported · AstraZeneca · starts Jul 25, 2024
| May 13, 2025 | An open-label long-term phase III extension study to assess the long-term safety and tolerability of dexpramipexole in participants with severe eosinophilic…Dexpramipexole | Areteia Therapeutics | Closed |
| May 9, 2025 | The imagine study: a phase 3b open label, single arm study to assess the effect of depemokimab on airway structure and function in asthma with type 2…Depemokimab (GSK3511294) | GSK | Ongoing |
| Dec 5, 2024 | Brisote: a multicentre, randomised, double-blind, parallel group, active-controlled, phase 3b study to evaluate the efficacy and safety of benralizumab 30 mg…Fasenra / Symbicort turbuhaler | AstraZeneca Pharmaceuticals | Closed |
| Nov 14, 2023 | A randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy, safety, and tolerability of dexpramipexole administered orally for…Dexpramipexole | Areteia Therapeutics | Closed |
| Nov 14, 2023 | A randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy, safety, and tolerability of dexpramipexole administered orally for…Dexpramipexole | Areteia Therapeutics | Closed |
| Dec 15, 2022 | A multicentre, randomised, double-blind, parallel group, placebo-controlled, time-to-first asthma exacerbation phase 3 efficacy and safety study of…Fasenra | AstraZeneca Pharmaceuticals | Closed |
| May 28, 2021 | A 52-week, randomised, double-blind, double-dummy, parallel group, multi-centre, non-inferiority study assessing exacerbation rate, additional measures of…GSK3511294 | GSK | Ongoing |
| Mar 19, 2021 | A phase 2, multicenter, randomized, double blind, placebo controlled, parallel group study to assess the safety, efficacy and pharmacodynamics of tev 53275…TEV-53275/ Proair digihaler | Teva Pharmaceutical Industries | Closed |
| Dec 17, 2020 | Efficacy of reslizumab dose escalation in patients with severe asthma and persistent sputum eosinophilia despite standard dose therapy.Cinqair | St Josephs Hospital Hamilton | Ongoing |
| Jul 10, 2019 | A phase 4, multicenter, randomized, double-blind, parallel group, placebo controlled study to evaluate the effect of benralizumab on structural and lung…MEDI-563 (benralizumab) | AstraZeneca Pharmaceuticals | Ongoing |
| Jan 8, 2018 | FasenraBenralizumab | AstraZeneca AB | EMA ↗ |
| Aug 15, 2016 | CinqaeroReslizumab | Teva B.V. | EMA ↗ |
| Dec 1, 2015 | NucalaMepolizumab | GlaxoSmithKline Trading Services Limited | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA